{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:04:57Z","timestamp":1789542297848,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11739-026-04410-1","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:29:00Z","timestamp":1780554540000},"page":"2165-2174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Robustness of placebo-controlled trials of extended-duration direct oral anticoagulant therapy for secondary venous thromboembolism prevention"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-1292","authenticated-orcid":false,"given":"Marco","family":"Zuin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Squizzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Temporelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"4410_CR1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11739-024-03550-6","volume":"19","author":"M Zuin","year":"2024","unstructured":"Zuin M, Rigatelli G, Temporelli P, Bilato C (2024) Trends in mortality related to venous thromboembolism in the European Union, 2012\u20132020. Intern Emerg Med 19:941\u2013949","journal-title":"Intern Emerg Med"},{"key":"4410_CR2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/jth.14477","volume":"17","author":"C Becattini","year":"2019","unstructured":"Becattini C, Giustozzi M, Cerd\u00e0 P, Cimini LA, Riera-Mestre A, Agnelli G (2019) Risk of recurrent venous thromboembolism after acute pulmonary embolism: role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis. J Thromb Haemost 17:1217\u20131228","journal-title":"J Thromb Haemost"},{"key":"4410_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/ATVBAHA.108.182428","volume":"29","author":"T Zhu","year":"2009","unstructured":"Zhu T, Martinez I, Emmerich J (2009) Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 29:298\u2013310","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4410_CR4","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jth.12301","volume":"11","author":"W Ageno","year":"2013","unstructured":"Ageno W, Squizzato A, Wells PS, B\u00fcller HR, Johnson G (2013) The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 11:1597\u20131602","journal-title":"J Thromb Haemost"},{"key":"4410_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jim\u00e9nez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, N\u00ed \u00c1inle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL, ESC Scientific Document Group (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543\u2013603","journal-title":"Eur Heart J"},{"key":"4410_CR6","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N van Es","year":"2014","unstructured":"van Es N, Coppens M, Schulman S, Middeldorp S, B\u00fcller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124:1968\u20131975","journal-title":"Blood"},{"key":"4410_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","volume":"43","author":"L Girardi","year":"2023","unstructured":"Girardi L, Wang TF, Ageno W, Carrier M (2023) Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism. Arterioscler Thromb Vasc Biol 43:824\u2013831","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4410_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","volume":"405","author":"F Couturaud","year":"2025","unstructured":"Couturaud F, Schmidt J, Sanchez O, Ballerie A, Sevestre MA, Meneveau N, Bertoletti L, Connault J, Benhamou Y, Constans J, Quemeneur T, Lap\u00e9bie FX, Pernod G, Picart G, Elias A, Doutrelon C, Neveux C, Khider L, Roy PM, Zuily S, Falvo N, Lacroix P, Emmerich J, Mah\u00e9 I, Boileau J, Yaici A, Le Jeune S, St\u00e9phan D, Plissonneau-Duquene P, Ray V, des D\u00e9serts MD, Belhadj-Chaidi R, Lamia B, Gruel Y, Presles E, Girard P, Tromeur C, Moustafa F, Rothstein V, Lacut K, Melac S, Barillot S, Mismetti P, Laporte S, Mottier D, Meyer G, Leroyer C, RENOVE Investigators (2025) Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet 405:725\u2013735","journal-title":"Lancet"},{"key":"4410_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood.2019002364","volume":"135","author":"C Kearon","year":"2020","unstructured":"Kearon C, Kahn SR (2020) Long-term treatment of venous thromboembolism. Blood 135:317\u2013325","journal-title":"Blood"},{"key":"4410_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/joim.20067","volume":"297","author":"K Glise Sandblad","year":"2025","unstructured":"Glise Sandblad K, Rosengren A, Schulman S, Roupe M, Sandstr\u00f6m TZ, Philipson J, Svennerholm K, Tavoly M (2025) Excess risk of bleeding in patients with venous thromboembolism on direct oral anticoagulants during initial and extended treatment versus population controls. J Intern Med 297:382\u2013399","journal-title":"J Intern Med"},{"key":"4410_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamasurg.2018.4318","volume":"154","author":"CJ Tignanelli","year":"2019","unstructured":"Tignanelli CJ, Napolitano LM (2019) The fragility index in randomized clinical trials as a means of optimizing patient care. JAMA Surg 154:74\u201379","journal-title":"JAMA Surg"},{"key":"4410_CR12","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1001\/jamainternmed.2020.4787","volume":"180","author":"A Chaitoff","year":"2020","unstructured":"Chaitoff A, Zheutlin A, Niforatos JD (2020) The fragility index and trial significance. JAMA Intern Med 180:1554","journal-title":"JAMA Intern Med"},{"key":"4410_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jclinepi.2013.10.019","volume":"67","author":"M Walsh","year":"2014","unstructured":"Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C, Molnar AO, Dattani ND, Burke A, Guyatt G, Thabane L, Walter SD, Pogue J, Devereaux PJ (2014) The statistical significance of randomized controlled trial results is frequently fragile: a case for a fragility index. J Clin Epidemiol 67:622\u2013628","journal-title":"J Clin Epidemiol"},{"key":"4410_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.12469","volume":"3","author":"MS Khan","year":"2020","unstructured":"Khan MS, Fonarow GC, Friede T, Lateef N, Khan SU, Anker SD, Harrell FE Jr, Butler J (2020) Application of the reverse fragility index to statistically nonsignificant randomized clinical trial results. JAMA Netw Open 3:e2012469","journal-title":"JAMA Netw Open"},{"key":"4410_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jclinepi.2019.03.012","volume":"111","author":"I Atal","year":"2019","unstructured":"Atal I, Porcher R, Boutron I, Ravaud P (2019) The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses. J Clin Epidemiol 111:32\u201340","journal-title":"J Clin Epidemiol"},{"key":"4410_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, AMPLIFY-EXT Investigators (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368:699\u2013708","journal-title":"N Engl J Med"},{"key":"4410_CR17","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499\u20132510","journal-title":"N Engl J Med"},{"key":"4410_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ, RE-MEDY Trial Investigators, RE-SONATE Trial Investigators (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368:709\u2013718","journal-title":"N Engl J Med"},{"key":"4410_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2509426","author":"G Piazza","year":"2025","unstructured":"Piazza G, Bikdeli B, Pandey AK, Krishnathasan D, Khairani CD, Bejjani A, Morrison RH, Hogan H, Rashedi S, Pfeferman M, Lou J, Fanikos J, Porio N, Rosenbaum L, Sobieszczyk P, Lan Z, Gerhard-Herman M, Campia U, Goldhaber SZ, HI-PRO Trial Investigators (2025) Apixaban for extended treatment of provoked venous thromboembolism. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2509426. (Epub ahead of print)","journal-title":"N Engl J Med"},{"key":"4410_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199903253401201","volume":"340","author":"C Kearon","year":"1999","unstructured":"Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901\u2013907","journal-title":"N Engl J Med"},{"key":"4410_CR21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1160\/TH08-07-0477","volume":"101","author":"MR Taliani","year":"2009","unstructured":"Taliani MR, Becattini C, Agnelli G, Prandoni P, Moia M, Bazzan M, Salvi R, Ageno W, Guazzaloca G, Imberti D, Silingardi M, Poggio R, Warfarin Optimal Duration Italian Trial (WODIT) Investigators (2009) Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. Thromb Haemost 101:596\u2013598","journal-title":"Thromb Haemost"},{"key":"4410_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.thromres.2020.04.036","volume":"191","author":"H Bounameaux","year":"2022","unstructured":"Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Schellong S, Mantovani LG, Prandoni P, Kakkar AK (2022) Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thromb Res 191:103\u2013112","journal-title":"Thromb Res"},{"key":"4410_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102101","volume":"4","author":"J Trujillo-Santos","year":"2025","unstructured":"Trujillo-Santos J, Ay C, Bikdeli B, Jim\u00e9nez D, Villalobos A, L\u00f3pez-Jim\u00e9nez L, P\u00e9rez-Pinar M, Pag\u00e1n-Escribano J, Ciammaichella M, Monreal M, RIETE Investigators (2025) Variation in venous thromboembolism outcomes based on primary cancer site: a RIETE registry analysis. JACC Adv 4:102101","journal-title":"JACC Adv"},{"issue":"7","key":"4410_CR24","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/jth.14837","volume":"18","author":"J Catella","year":"2020","unstructured":"Catella J, Bertoletti L, Mismetti P, Ollier E, Samperiz A, Soler S, Suri\u00f1ach JM, Mah\u00e9 I, Lorente MA, Braester A, Monreal M, investigators of the RIETE registry (2020) Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. J Thromb Haemost 18(7):1728\u20131737. https:\/\/doi.org\/10.1111\/jth.14837. (Epub 2020 May 11. PMID: 32299150)","journal-title":"J Thromb Haemost"},{"key":"4410_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","volume":"44","author":"MA de Winter","year":"2023","unstructured":"de Winter MA, B\u00fcller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager KAH, Kakkar AK, Middeldorp S, Raskob GE, S\u00f8rensen HT, Visseren FLJ, Wells PS, Dorresteijn JAN, Nijkeuter M, VTE-PREDICT study group (2023) Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J 44:1231\u20131244","journal-title":"Eur Heart J"},{"key":"4410_CR26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","volume":"392","author":"I Mah\u00e9","year":"2025","unstructured":"Mah\u00e9 I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, L\u00f3pez-N\u00fa\u00f1ez JJ, Otero-Candelera R, Le Gal G, Yeo E, Righini M, Robert-Ebadi H, Huisman MV, Klok FA, Westerweel P, Agnelli G, Becattini C, Bamias A, Syrigos K, Szmit S, Torbicki A, Verhamme P, Maraveyas A, Cohen AT, Ay C, Chapelle C, Meyer G, Couturaud F, Mismetti P, Girard P, Bertoletti L, Laporte S, API-CAT Investigators (2025) Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med 392:1363\u20131373","journal-title":"N Engl J Med"},{"key":"4410_CR27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, EINSTEIN CHOICE Investigators (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 376:1211\u20131222","journal-title":"N Engl J Med"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04410-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:33:57Z","timestamp":1789540437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04410-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4410"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04410-1","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Piazza has received research support paid to his institution from Bristol-Myers Squibb\/Pfizer Alliance, Bayer, Janssen, Alexion, Amgen, Boston Scientific Corporation, and Esperion; funding from grant 1R01HL164717-01; and consulting fees from Bristol-Myers Squibb\/Pfizer Alliance, Boston Scientific Corporation, Janssen, NAMSA, Penumbar, Thrombolex, Amgen, and Regeneron. Walter Ageno has participated in advisory boards for Astra-Zeneca, Bayer, BMS-Pfizer, Sanofi, and Viatris. Dr. Squizzato reports having received lecture fees from Daiichi Sankyo, Bayer, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Techdow, Werfen, Alexion, Roche, and Viatris, and having served on advisory boards for Bayer, Viatris, and Daiichi Sankyo.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}}]}}